



Alliance for
Children's Therapeutics



Seattle Children's
HOSPITAL • RESEARCH • FOUNDATION

Research Institute

PRESS RELEASE

Alliance for Children's Therapeutics to present its Pediatric Program at the *Partnering for Cures* Meeting Nov. 18

Talk to focus on collaboration to speed development of new medications for pediatric diseases

Seattle, WA, Nov. 6, 2014 – The [Alliance for Children's Therapeutics](http://www.childrenstherapeutics.org) (ACT) today announced it has been selected to present at the *FasterCures*' sixth annual [Partnering for Cures](http://www.fastercures.org) meeting. The talk will occur on Nov. 18 at 10 a.m. ET at the Grand Hyatt New York. It will focus on ACT's first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with autoimmune diseases.

The conference is slated to bring together leaders from all sectors of the medical research enterprise for the purpose of fostering collaborations to discover medical breakthroughs. Some other conference presenters include the Foundation for the National Institutes of Health, Johns Hopkins University, Mayo Clinic and the National Multiple Sclerosis Society.

ACT was launched in June by Seattle Children's Research Institute and biotechnology company Kineta. Its first research target, using Kineta's lead drug ShK-186, was lupus nephritis, an autoimmune disease that causes kidney inflammation. Early ACT pre-clinical research using cells of pediatric patients with lupus nephritis have shown promising results, and the ACT team expects to begin its first clinical trial in 2015. There are currently no FDA-approved treatments for treating pediatric lupus nephritis.

Kineta CEO and President Charles Magness and Seattle Children's Research Institute's Vice President of Community and Strategic Initiatives Stephanie Axelrod, will present the ACT collaboration, initial research progress and future goals.

This year's *Partnering for Cures* meeting is convened by *FasterCures*, the DC-based center of the Milken Institute.

Additional Information: Alliance for Children's Therapeutics Website: www.childrenstherapeutics.org

About Kineta, Inc. is a Seattle-based privately held Biotechnology Company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world-class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on

targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

About Seattle Children's Research Institute

Located in downtown Seattle's biotech corridor, Seattle Children's Research Institute is pushing the boundaries of medical research to find cures for pediatric diseases and improve outcomes for children all over the world. Internationally recognized investigators and staff at the research institute are advancing new discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics, among others. As part of Seattle Children's Hospital, the research institute brings together leading minds in pediatric research to provide patients with the best care possible. Seattle Children's serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. For more information, visit <http://www.seattlechildrens.org/research>.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for clinical studies, anticipated drug effects in human subjects and financial performance. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, intellectual property protection and enforcement, efficacy and demand for the products, clinical testing and regulatory approval, changes legislative, fiscal, and other regulatory measures, competition from other drug development companies, our ability to raise funds on acceptable terms, and our ability to recruit and retain scientists and key personnel. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact for Media:

- Seattle Children's Research Institute: pressinquiries@seattlechildrens.org, 206-987-4500
- Kineta: Dan Eramian, Deramian@kineta.us, 206-378-0400